pyridostigmine 是一种乙酰胆碱酯酶抑制剂，可通过增加突触后运动终板的乙酰胆碱来治疗重症肌无力。

Pyridostigmine is an acetylcholinesterase inhibitor that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.

Pyridostigmine holds promise for the treatment of various gastrointestinal symptoms in SSc patients, particularly in patients with refractory constipation. Though side effects may limit its use, most patients who experienced benefit chose to continue therapy[1].

155-97-5

C9H13BrN2O2

261.116

Regonol;Pyridostigminum;PyridostigmineBromine;UNII-19QM69HH21;Mestinon-SR;pyridostigmine

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years